{
  "medicare_pathways": [
    {
      "id": "ncd",
      "name": "National Coverage Determination (NCD)",
      "description": "CMS's formal coverage decision applying nationally to all Medicare beneficiaries",
      "typical_timeline_months": "6-12",
      "coverage_outcomes": [
        {
          "type": "covered",
          "description": "Reasonable and necessary for diagnosis/treatment"
        },
        {
          "type": "non_covered",
          "description": "Not meeting coverage criteria"
        },
        {
          "type": "ced",
          "name": "Coverage with Evidence Development",
          "description": "Covered only in approved clinical studies"
        }
      ]
    },
    {
      "id": "tcet",
      "name": "Transitional Coverage for Emerging Technologies",
      "effective_date": "2024-08-12",
      "description": "New pathway for FDA Breakthrough Devices providing expedited national coverage",
      "eligibility": [
        "FDA Breakthrough Device Designation",
        "FDA market authorization (approved/cleared)",
        "Manufacturer opts in"
      ],
      "benefits": [
        "Early evidence preview before FDA approval",
        "Expedited NCD (target 6 months post-FDA)",
        "Transitional coverage up to 5+ years",
        "Evidence development during coverage"
      ],
      "process": [
        {
          "step": 1,
          "name": "Pre-FDA Engagement",
          "description": "Manufacturer requests TCET participation"
        },
        {
          "step": 2,
          "name": "Early Evidence Preview",
          "description": "CMS reviews evidence before FDA decision"
        },
        {
          "step": 3,
          "name": "Coverage Pathway Discussion",
          "description": "Best pathway determined with CMS"
        },
        {
          "step": 4,
          "name": "Post-FDA NCD Process",
          "description": "NCD begins after FDA authorization"
        },
        {
          "step": 5,
          "name": "Proposed NCD",
          "description": "Within 6 months of FDA authorization"
        },
        {
          "step": 6,
          "name": "Evidence Period",
          "description": "5+ years coverage while data collected"
        }
      ],
      "bci_eligible_companies": [
        "Blackrock Neurotech (MoveAgain)",
        "Neuralink (N1, Blindsight)",
        "Synchron (Stentrode)",
        "Cognixion (ONE)"
      ]
    },
    {
      "id": "lcd",
      "name": "Local Coverage Determination",
      "description": "Coverage decisions by Medicare Administrative Contractors for their regions",
      "advantages": [
        "Faster than NCDs",
        "Can establish coverage precedent",
        "Regional de facto national coverage possible"
      ],
      "disadvantages": [
        "Geographic variation",
        "Less binding than NCD",
        "Can be overridden"
      ]
    }
  ],
  "benefit_categories": [
    {
      "id": "dme",
      "name": "Durable Medical Equipment (DME)",
      "regulation": "21 CFR ยง 414.202",
      "criteria": [
        "Withstand repeated use",
        "Primarily medical purpose",
        "Generally not useful without illness/injury",
        "Appropriate for home use"
      ],
      "bci_examples": [
        {
          "device": "IpsiHand",
          "company": "Neurolutions",
          "status": "Classified as DME by CMS (Jan 2025)"
        }
      ]
    },
    {
      "id": "prosthetic",
      "name": "Prosthetic Devices",
      "regulation": "SSA ยง 1861(s)(8)",
      "criteria": [
        "Replaces all or part of internal body organ",
        "Includes replacement of organ function"
      ],
      "bci_relevance": "Implanted BCIs may qualify as prosthetics replacing neural communication function"
    }
  ],
  "dbs_reimbursement_precedent": {
    "description": "Deep Brain Stimulation provides precedent for implantable neural device reimbursement",
    "covered_indications": [
      "Parkinson's disease",
      "Essential tremor",
      "Dystonia",
      "Obsessive-compulsive disorder",
      "Epilepsy (adjunctive)"
    ],
    "example_cpt_codes": [
      {
        "code": "61867",
        "description": "Implant cranial neurostimulator electrode array"
      },
      {
        "code": "61885",
        "description": "Insertion of cranial neurostimulator pulse generator"
      },
      {
        "code": "95836",
        "description": "Programming, initial"
      },
      {
        "code": "95837",
        "description": "Programming, subsequent"
      }
    ],
    "estimated_reimbursement": {
      "implantation_procedure": "$20,000-40,000",
      "device_payment": "$25,000-50,000"
    }
  },
  "bci_coverage_milestones": [
    {
      "date": "2021",
      "event": "IpsiHand FDA De Novo classification",
      "company": "Neurolutions"
    },
    {
      "date": "2023-05",
      "event": "Cognixion CMS DME supplier accreditation",
      "company": "Cognixion"
    },
    {
      "date": "2024-08",
      "event": "CMS TCET pathway finalized",
      "significance": "New coverage pathway for Breakthrough Devices"
    },
    {
      "date": "2025-01",
      "event": "IpsiHand CMS coverage decision - first BCI with dedicated reimbursement",
      "company": "Neurolutions",
      "details": {
        "benefit_category": "DME",
        "cpt_code": "Dedicated code assigned"
      }
    }
  ],
  "private_payor_considerations": {
    "coverage_factors": [
      "FDA approval status",
      "Medical necessity evidence",
      "Cost-effectiveness vs alternatives",
      "Provider network expertise",
      "Patient demand/advocacy"
    ],
    "strategies": [
      {
        "name": "Self-insured employer targeting",
        "rationale": "More flexibility for innovative treatments"
      },
      {
        "name": "Centers of Excellence programs",
        "rationale": "Concentrate at high-volume centers with negotiated rates"
      },
      {
        "name": "Outcomes-based contracts",
        "rationale": "Payment tied to clinical outcomes reduces payor risk"
      }
    ]
  }
}
